Stephen Santoro

TL;DR: Tumours from a large cohort of patients with metastatic urothelial cancer who were treated with an anti-PD-L1 agent were examined and major determinants of clinical outcome were identified and suggested that TGFβ shapes the tumour microenvironment to restrain anti-tumour immunity by restricting T-cell infiltration.

TL;DR: T tumor paracrine mechanisms establish a tumor endothelial death barrier, which has a critical role in establishing immune tolerance and determining the fate of tumors.

TL;DR: It is demonstrated that breast tumors contain multiple populations of FAP-expressing stromal cells of dichotomous function, phenotype, and location, which may lead to better designed immunotherapies.

TL;DR: It is demonstrated that VPA-induced upregulation ofNKG2DL expression enhances the immune recognition of ovarian cancer cells by engineered NKG2D CAR T cells, and rationalizes the use of VPA in combination with NKG 2DL-targeted immunotherapy in ovarian cancer.

TL;DR: The ability of chimeric antigen receptor–bearing T cells to recognize human prostate–specific membrane antigen on endothelial targets in vitro as well as in vivo is described, providing a strong rationale for the use of CAR T cells as agents of tumor vascular disruption, specifically those targeting PSMA.